Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.62 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730772 | 0.89 | TACR1 (0.66) | TACR1TACR3USP2ABCB1MITF | |
| SCHEMBL7684256 | 0.81 | TACR1 (0.55) | TACR1TACR3USP2CYP3A4TSHR | |
| SCHEMBL22901699 | 0.79 | TACR1 (0.71) | TACR1TACR3RHOCRHOA | |
| SCHEMBL14217474 | 0.78 | TACR1 (0.61) | TACR1TACR3USP2ABCB1MITF | |
| SCHEMBL9112230 | 0.77 | TACR1 (0.78) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL7823087 | 0.77 | TACR1 (0.66) | TACR1TACR3USP2MITF | |
| SCHEMBL9113036 | 0.77 | TACR1 (0.78) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL8480058 | 0.77 | CA1 (0.66) | TACR1TACR3 | |
| SCHEMBL13818185 | 0.76 | TACR1 (0.77) | TACR1TACR3USP2RHOCRHOA | |
| Hydrochloric Acid SCHEMBL8475576 | 0.76 | TACR1 (0.64) | TACR1TACR3USP2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| EP-1635833-A1 | COMBINATIONS FOR OPIOID-BASED TREATMENT OF PAIN COMPRISING 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110451-A1 | COMBINATIONS FOR OPIOID-BASED TREATMENT OF PAIN COMPRISING 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | disclosed |
| US-6521621-B1 | Tachykinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-02-18 | — | — | US | disclosed |
| US-RE37886-E1 | 1-(1,2-Disubstituted piperidinyl)-4-substituted piperazine derivatives | JANSSEN PHARMACEUTICALS, N.V. (BE) | 2002-10-15 | — | — | US | disclosed |
| US-6197772-B1 | TACHYKININS ANTAGONIST; ANTIINFLAMMATION AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-06 | — | — | US | disclosed |
| EP-0862566-B1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0862566-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997016440-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | OPRL1, OPRK1, OPRM1 | TACR1 28/4885TACR3 514/4885USP2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.